Dr. Lal Pathlabs Share Price
Dr. Lal Pathlabs Ltd.
Performance of Dr. Lal Pathlabs Shares 
Open Price
Prev. Close
Volume
Value
About Dr. Lal Pathlabs
Dr Lal PathLabs was started in 1949, by the late S. K. Lal. The company has 200 laboratories and diagnostic centres with approximately 1500 collection centres across India.[1] They have also worked with BD India to open a "Centre of Excellence in Phlebotomy", a centre for training healthcare in the process of safely collecting blood samples. The main operation of Dr Lal PathLabs deals with the performing of diagnosis and testing, including routine tests (including blood tests), specialized tests (e.g., viral and bacterial infection tests) and preventive screenings.
In 2013, Dr Lal PathLabs was awarded Best Diagnostic Service Company by VCCircle. VCCircle stated: "Dr Lal PathLabs has been able to create a brand with scale in a fragmented market. Dr Lal PathLabs is present in 800 cities with 2,000 collections centres, and caters to around 10 million patients a year."
In 2014, Dr Lal PathLabs acquired the APL Clinical Institute of Clinical Laboratory & Research Private Limited. Click Here to know today’s Dr Lal PathLab Ltd’s share price.
In 2013, Dr Lal PathLabs was awarded Best Diagnostic Service Company by VCCircle. VCCircle stated: "Dr Lal PathLabs has been able to create a brand with scale in a fragmented market. Dr Lal PathLabs is present in 800 cities with 2,000 collections centres, and caters to around 10 million patients a year."
In 2014, Dr Lal PathLabs acquired the APL Clinical Institute of Clinical Laboratory & Research Private Limited. Click Here to know today’s Dr Lal PathLab Ltd’s share price.
Fundamentals of Dr. Lal Pathlabs Shares
Market Cap |
P/E Ratio |
P/B Ratio |
Industry P/E |
|---|---|---|---|
Rs. 14925.35 Cr |
80.56 |
19.17 |
168.43 |
ROE |
EPS (TTM) |
Dividend Yield |
Book Value |
|---|---|---|---|
25.93 % |
41.28 |
0.74 % |
193.06 |
Similar Stocks
FAQ’s
How to buy Dr. Lal Pathlabs Ltd. shares?
All you have to do to buy Dr. Lal Pathlabs Ltd. share is download Nuuu app, create a demat account, and get your KYC documents verified online.
Can I buy Dr. Lal Pathlabs Ltd. shares?
Yes you can buy Dr. Lal Pathlabs Ltd. shares, all you need is to have a verified demat account with Nuuu. And enjoy benefits like free brokerage credits and more.
What is the Market Cap of Dr. Lal Pathlabs Ltd. shares?
As of 20 Mar`23 the Market Cap of Dr. Lal Pathlabs Ltd. is 14925.35.
What is the PE and PB ratio of Dr. Lal Pathlabs Ltd. stock?
As of 20 Mar`23 the PE is 80.56 and PB is 19.17.
Dr. Lal Pathlabs - Quaterly Results
Publish Date: 08/11/2022
The revenue slipped marginally during the September 2022 quarter. A decline of about Rs. 4669.00 millions was observed as compared to Rs. 4704.00 millions during the corresponding quarter last year.A slender decline of -16.29% was recorded to Rs. 786.00 millions from Rs. 939.00 millions in the corresponding previous quarter.The company reported a degrowth in operating Profit to 1378.00 millions from 1483.00 millions.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 4669.00 | 4704.00 | -0.74 | 9062.00 | 10353.00 | -12.47 | 18727.00 | 14905.00 | 25.64 |
| Other Income | 76.00 | 153.00 | -50.33 | 264.00 | 288.00 | -8.33 | 530.00 | 513.00 | 3.31 |
| PBIDT | 1378.00 | 1483.00 | -7.08 | 2660.00 | 3347.00 | -20.53 | 5632.00 | 4587.00 | 22.78 |
| Interest | 100.00 | 43.00 | 132.56 | 177.00 | 87.00 | 103.45 | 285.00 | 148.00 | 92.57 |
| PBDT | 1278.00 | 1440.00 | -11.25 | 2483.00 | 3260.00 | -23.83 | 5347.00 | 4439.00 | 20.46 |
| Depreciation | 214.00 | 181.00 | 18.23 | 402.00 | 349.00 | 15.19 | 753.00 | 698.00 | 7.88 |
| PBT | 1064.00 | 1259.00 | -15.49 | 2081.00 | 2911.00 | -28.51 | 4594.00 | 3741.00 | 22.80 |
| TAX | 278.00 | 320.00 | -13.12 | 499.00 | 739.00 | -32.48 | 1153.00 | 940.00 | 22.66 |
| Deferred Tax | -63.00 | -6.00 | 950.00 | -75.00 | -77.00 | -2.60 | -27.00 | -45.00 | -40.00 |
| PAT | 786.00 | 939.00 | -16.29 | 1582.00 | 2172.00 | -27.16 | 3441.00 | 2801.00 | 22.85 |
| Equity | 834.00 | 833.00 | 0.12 | 834.00 | 833.00 | 0.12 | 833.00 | 833.00 | 0.00 |
| PBIDTM(%) | 29.51 | 31.53 | -6.38 | 29.35 | 32.33 | -9.20 | 30.07 | 30.77 | -2.28 |
Dr. Lal Pathlabs - Quaterly Results
Publish Date: 08/11/2022
The revenue slipped marginally during the September 2022 quarter. A decline of about Rs. 4669.00 millions was observed as compared to Rs. 4704.00 millions during the corresponding quarter last year.The Company's Net profit for the September 2022 quarter have declined marginally to Rs. 786.00 millions as against Rs. 939.00 millions reported during the corresponding quarter ended.The Operating Profit of the company witnessed a decrease to 1378.00 millions from 1483.00 millions.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 4669.00 | 4704.00 | -0.74 | 9062.00 | 10353.00 | -12.47 | 18727.00 | 14905.00 | 25.64 |
| Other Income | 76.00 | 153.00 | -50.33 | 264.00 | 288.00 | -8.33 | 530.00 | 513.00 | 3.31 |
| PBIDT | 1378.00 | 1483.00 | -7.08 | 2660.00 | 3347.00 | -20.53 | 5632.00 | 4587.00 | 22.78 |
| Interest | 100.00 | 43.00 | 132.56 | 177.00 | 87.00 | 103.45 | 285.00 | 148.00 | 92.57 |
| PBDT | 1278.00 | 1440.00 | -11.25 | 2483.00 | 3260.00 | -23.83 | 5347.00 | 4439.00 | 20.46 |
| Depreciation | 214.00 | 181.00 | 18.23 | 402.00 | 349.00 | 15.19 | 753.00 | 698.00 | 7.88 |
| PBT | 1064.00 | 1259.00 | -15.49 | 2081.00 | 2911.00 | -28.51 | 4594.00 | 3741.00 | 22.80 |
| TAX | 278.00 | 320.00 | -13.12 | 499.00 | 739.00 | -32.48 | 1153.00 | 940.00 | 22.66 |
| Deferred Tax | -63.00 | -6.00 | 950.00 | -75.00 | -77.00 | -2.60 | -27.00 | -45.00 | -40.00 |
| PAT | 786.00 | 939.00 | -16.29 | 1582.00 | 2172.00 | -27.16 | 3441.00 | 2801.00 | 22.85 |
| Equity | 834.00 | 833.00 | 0.12 | 834.00 | 833.00 | 0.12 | 833.00 | 833.00 | 0.00 |
| PBIDTM(%) | 29.51 | 31.53 | -6.38 | 29.35 | 32.33 | -9.20 | 30.07 | 30.77 | -2.28 |
Dr. Lal Pathlabs - Quaterly Results
Publish Date: 08/11/2022
The revenue slipped marginally during the September 2022 quarter. A decline of about Rs. 4669.00 millions was observed as compared to Rs. 4704.00 millions during the corresponding quarter last year.The Company's Net profit for the September 2022 quarter have declined marginally to Rs. 786.00 millions as against Rs. 939.00 millions reported during the corresponding quarter ended.The Operating Profit of the company witnessed a decrease to 1378.00 millions from 1483.00 millions.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 4669.00 | 4704.00 | -0.74 | 9062.00 | 10353.00 | -12.47 | 18727.00 | 14905.00 | 25.64 |
| Other Income | 76.00 | 153.00 | -50.33 | 264.00 | 288.00 | -8.33 | 530.00 | 513.00 | 3.31 |
| PBIDT | 1378.00 | 1483.00 | -7.08 | 2660.00 | 3347.00 | -20.53 | 5632.00 | 4587.00 | 22.78 |
| Interest | 100.00 | 43.00 | 132.56 | 177.00 | 87.00 | 103.45 | 285.00 | 148.00 | 92.57 |
| PBDT | 1278.00 | 1440.00 | -11.25 | 2483.00 | 3260.00 | -23.83 | 5347.00 | 4439.00 | 20.46 |
| Depreciation | 214.00 | 181.00 | 18.23 | 402.00 | 349.00 | 15.19 | 753.00 | 698.00 | 7.88 |
| PBT | 1064.00 | 1259.00 | -15.49 | 2081.00 | 2911.00 | -28.51 | 4594.00 | 3741.00 | 22.80 |
| TAX | 278.00 | 320.00 | -13.12 | 499.00 | 739.00 | -32.48 | 1153.00 | 940.00 | 22.66 |
| Deferred Tax | -63.00 | -6.00 | 950.00 | -75.00 | -77.00 | -2.60 | -27.00 | -45.00 | -40.00 |
| PAT | 786.00 | 939.00 | -16.29 | 1582.00 | 2172.00 | -27.16 | 3441.00 | 2801.00 | 22.85 |
| Equity | 834.00 | 833.00 | 0.12 | 834.00 | 833.00 | 0.12 | 833.00 | 833.00 | 0.00 |
| PBIDTM(%) | 29.51 | 31.53 | -6.38 | 29.35 | 32.33 | -9.20 | 30.07 | 30.77 | -2.28 |
Dr. Lal Pathlabs - Quaterly Results
Publish Date: 02/02/2023
The total revenue for the quarter ended December 2022 remained nearly unchanged at Rs. 4284.00 millions.A meek growth of 1.13% was reported for the quarter ended December 2022 to Rs. 624.00 millions from Rs. 617.00 millions.Operating profit for the quarter ended December 2022 rose to 1130.00 millions as compared to 1108.00 millions of corresponding quarter ended December 2021.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 4284.00 | 4225.00 | 1.40 | 13346.00 | 14578.00 | -8.45 | 18727.00 | 14905.00 | 25.64 |
| Other Income | 86.00 | 113.00 | -23.89 | 350.00 | 401.00 | -12.72 | 530.00 | 513.00 | 3.31 |
| PBIDT | 1130.00 | 1108.00 | 1.99 | 3790.00 | 4455.00 | -14.93 | 5632.00 | 4587.00 | 22.78 |
| Interest | 83.00 | 87.00 | -4.60 | 260.00 | 174.00 | 49.43 | 285.00 | 148.00 | 92.57 |
| PBDT | 1047.00 | 1021.00 | 2.55 | 3530.00 | 4281.00 | -17.54 | 5347.00 | 4439.00 | 20.46 |
| Depreciation | 206.00 | 189.00 | 8.99 | 608.00 | 538.00 | 13.01 | 753.00 | 698.00 | 7.88 |
| PBT | 841.00 | 832.00 | 1.08 | 2922.00 | 3743.00 | -21.93 | 4594.00 | 3741.00 | 22.80 |
| TAX | 217.00 | 215.00 | 0.93 | 716.00 | 954.00 | -24.95 | 1153.00 | 940.00 | 22.66 |
| Deferred Tax | -1.00 | 23.00 | -104.35 | -76.00 | -54.00 | 40.74 | -27.00 | -45.00 | -40.00 |
| PAT | 624.00 | 617.00 | 1.13 | 2206.00 | 2789.00 | -20.90 | 3441.00 | 2801.00 | 22.85 |
| Equity | 834.00 | 833.00 | 0.12 | 834.00 | 833.00 | 0.12 | 833.00 | 833.00 | 0.00 |
| PBIDTM(%) | 26.38 | 26.22 | 0.58 | 28.40 | 30.56 | -7.07 | 30.07 | 30.77 | -2.28 |
Dr. Lal Pathlabs informs about analyst meet
Publish Date: 22/08/2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal Pathlabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s). Dates of this meeting/call are subject to change due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information will be shared during the meetings.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 29/08/2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s). Dates of the aforesaid meeting/call are subject to change due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information will be shared during the meeting.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 16/09/2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed about the details of proposed
schedule of Analyst/ Institutional Investor meeting(s) to be held on 19th September 2022.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about investor meeting
Publish Date: 19/09/2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s). Dates of the aforesaid meeting/call are subject to change due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information will be shared during the meetings.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about board meeting
Publish Date: 01/11/2022
Dr. Lal PathLabs has informed that a meeting of the Board of Directors is scheduled to be held on Tuesday, November 08, 2022 to consider and approve the Un-Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Half Year ended September 30, 2022.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about newspaper advertisement
Publish Date: 09/11/2022
Pursuant to the Regulation 30 of the SEBI Listing Regulations, Dr. Lal PathLabs has informed that it attached copies of newspaper advertisement of Financial Results of the Company for the quarter and half year ended on September 30, 2022, published in Financial Express and Jansatta on November 09, 2022.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 21/11/2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s). Dates of the aforesaid meeting/call are subject to change due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information will be shared during the meetings.
The above information is a part of company’s filings submitted to BSE.
Dr Lal PathLabs informs about disclosure
Publish Date: 23/11/2022
Dr Lal PathLabs has informed that the exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Wasatch Advisors, Inc.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 05/12/2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that the details of proposed schedule of Analyst/ Institutional Investor meeting(s) as on December 5, 2022, and December 6, 2022 are enclosed.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 07/12/2022
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s). Dates of the aforesaid meeting/call are subject to change due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information will be shared during the meetings.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about closure of trading window
Publish Date: 28/12/2022
Dr. Lal PathLabs has informed that as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window, shall be closed from January 01, 2023 and would be re-opened after 48 hours from the date of announcement/ declaration of Financial Results for the Quarter and Nine Months ending December 31, 2022.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet intimation
Publish Date: 27/01/2023
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Dr. Lal PathLabs has informed that it attached the invite of the Conference Call for Investors/ Analysts to be held on Thursday, February 02, 2023 at 05:00 pm IST to discuss the financial and operating performance for Q3 & 9M FY23.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal Pathlabs moves up as its arm gets nod to acquire further 10% stake in APRL PathLabs
Publish Date: 31/01/2023
The Board of Directors of the company in their meeting held on January 30, 2023 approved the same
Dr. Lal Pathlabs is currently trading at Rs. 2077.40, up by 17.35 points or 0.84% from its previous closing of Rs. 2060.05 on the BSE.
The scrip opened at Rs. 2089.95 and has touched a high and low of Rs. 2089.95 and Rs. 2038.95 respectively. So far 778 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3270.30 on 02-Feb-2022 and a 52 week low of Rs. 1805.10 on 26-May-2022.
Last one week high and low of the scrip stood at Rs. 2117.65 and Rs. 2025.00 respectively. The current market cap of the company is Rs. 17177.15 crore.
The promoters holding in the company stood at 55.05%, while Institutions and Non-Institutions held 31.99% and 12.96% respectively.
Dr. Lal Pathlabs’ Wholly Owned Subsidiary--- PathLabs Unifiers (PUPL) has received approval for the acquisition of further 10% equity stake in its Subsidiary Company i.e. APRL PathLabs (APRL). Object of acquisition is to strengthen the company’s presence in the state of Gujarat, India. Cost of acquisition is around Rs 7.50 Million. Post this acquisition, total equity stake of PUPL in APRL will increase from 70% to 80%. The Board of Directors of the company in their meeting held on January 30, 2023 approved the same.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.
Dr. Lal PathLabs informs about institutional investor meeting
Publish Date: 06/02/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that the Analyst/ Institutional Investor meeting(s) to be held on February 07, 2023 with Stewart. Dates of the aforesaid meeting/call are subject to change due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information will be shared during the meetings.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 07/02/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s) as on February 09, 2023, and February 10, 2023.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 17/02/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s) scheduled on February 17, 2023. Dates of the aforesaid meeting/call are subject to change due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information will be shared during the meetings.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 23/02/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s).
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 02/03/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it attached the details of proposed schedule of Analyst/ Institutional Investor meeting(s).
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 15/03/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that Analyst/ Institutional Investor meeting(s) to be held on March 15, 2023 with Polen Capital, London in Gurugram in the form One-on-One Meeting.
The above information is a part of company’s filings submitted to BSE.
Dr. Lal PathLabs jumps on selecting Kyndryl to manage IT infrastructure stack
Publish Date: 15/03/2023
Post onboarding, Kyndryl has been instrumental in managing the multiple cloud platforms
Dr. Lal Pathlabs is currently trading at Rs. 1851.40, up by 16.15 points or 0.88% from its previous closing of Rs. 1835.25 on the BSE.
The scrip opened at Rs. 1849.95 and has touched a high and low of Rs. 1871.70 and Rs. 1835.15 respectively. So far 9255 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2870.00 on 28-Apr-2022 and a 52 week low of Rs. 1781.15 on 14-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1929.85 and Rs. 1781.15 respectively. The current market cap of the company is Rs. 15433.06 crore.
The promoters holding in the company stood at 55.05%, while Institutions and Non-Institutions held 31.99% and 12.96% respectively.
Dr. Lal PathLabs has selected Kyndryl, the world’s largest IT infrastructure services provider, to manage its IT infrastructure stack, including both the on-premises IT environment and cloud infrastructure across multiple hyperscaler cloud service providers. Post onboarding, Kyndryl has been instrumental in managing the multiple cloud platforms that play a key role in Dr Lal PathLabs’ digital transformation initiatives to drive business growth.
Kyndryl provides a single pane view of server utilization, service requests, ticketing lifecycle, incident analysis, and also recommends proactive remediation. Offering a unified view of their infrastructure utilization on-premises and across multiple public cloud environments has improved service availability and helped Dr. Lal Pathlabs reduce IT incidents by a substantial margin. Kyndryl has also integrated compliance checks such as inventory management, patching, and security health, which have helped achieve continuous compliance within Dr. Lal PathLabs’ cloud environment and security posture.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.
Dr. Lal PathLabs informs about analyst meet
Publish Date: 17/03/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has informed that it enclosed the details of proposed schedule of Analyst/ Institutional Investor meeting(s).
The above information is a part of company’s filings submitted to BSE.
Board Meeting
Publish Date: 02/02/2023
Quarterly Results
Ex Dividend
Publish Date: 22/06/2022
Rs.6.0000 per share(60%)Final Dividend
Board Meeting
Publish Date: 17/05/2022
Audited Results & Final Dividend
Board Meeting
Publish Date: 10/02/2022
Quarterly Results
Board Meeting
Publish Date: 26/10/2021
Quarterly Results
Ex Dividend
Publish Date: 18/08/2021
Rs.6.0000 per share(60%)Interim Dividend
Board Meeting
Publish Date: 30/07/2021
Interim Dividend & Quarterly Results
Ex Dividend
Publish Date: 20/07/2021
Rs.8.0000 per share(80%)Final Dividend
Board Meeting
Publish Date: 21/05/2021
Audited Results & Final Dividend
Dr. Lal Pathlabs’ arm gets nod to acquire further 10% stake in APRL PathLabs
Publish Date: 31/01/2023
The Board of Directors of the company in their meeting held on January 30, 2023 approved the same
Dr. Lal Pathlabs’ Wholly Owned Subsidiary--- PathLabs Unifiers (PUPL) has received approval for the acquisition of further 10% equity stake in its Subsidiary Company i.e. APRL PathLabs (APRL). Object of acquisition is to strengthen the company’s presence in the state of Gujarat, India. Cost of acquisition is around Rs 7.50 Million. Post this acquisition, total equity stake of PUPL in APRL will increase from 70% to 80%. The Board of Directors of the company in their meeting held on January 30, 2023 approved the same.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.
Dr. Lal PathLabs selects Kyndryl to manage IT infrastructure stack
Publish Date: 15/03/2023
Post onboarding, Kyndryl has been instrumental in managing the multiple cloud platforms
Dr. Lal PathLabs has selected Kyndryl, the world’s largest IT infrastructure services provider, to manage its IT infrastructure stack, including both the on-premises IT environment and cloud infrastructure across multiple hyperscaler cloud service providers. Post onboarding, Kyndryl has been instrumental in managing the multiple cloud platforms that play a key role in Dr Lal PathLabs’ digital transformation initiatives to drive business growth.
Kyndryl provides a single pane view of server utilization, service requests, ticketing lifecycle, incident analysis, and also recommends proactive remediation. Offering a unified view of their infrastructure utilization on-premises and across multiple public cloud environments has improved service availability and helped Dr. Lal Pathlabs reduce IT incidents by a substantial margin. Kyndryl has also integrated compliance checks such as inventory management, patching, and security health, which have helped achieve continuous compliance within Dr. Lal PathLabs’ cloud environment and security posture.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.
Open A Free Demat Account
Sign Up
